

---

**BLONDIN v. COLOPLAST CANADA CORPORATION, No. 500-06-001051-206**  
**NOTICE TO CLASS MEMBERS**

---

**PLEASE READ THIS NOTICE CAREFULLY AS IT MAY AFFECT YOUR RIGHTS**

**NOTICE**

A settlement (the “**Settlement Agreement**”) has been reached in a Quebec class action involving mesh devices manufactured by Coloplast Canada Corporation (the “**Defendant**”) to treat Stress Urinary Incontinence (“SUI”) and Pelvic Organ Prolapse (“POP”).

The class action applies to all persons residing in Quebec who have used transvaginal mesh products manufactured, marketed, distributed and/or sold in whole or in part by the Defendant (namely **Aris, Exair, Minitape, Novasilk, Omnisure, Restorelle Direct Fix Anterior, Restorelle Direct Fix Posterior, Supris, T-Sling**) and who allege they have suffered damages following the implantation of these mesh products. To be eligible to partake in the Settlement Agreement, members with a prospective claim needed to have received their surgical mesh implant after November 14, 2016 and up to April 27, 2023, or to have undergone relevant medical care as documented by medical records after November 14, 2016.

A settlement approval hearing took place at the Montreal Courthouse on September 6, 2023 to approve the Settlement Agreement in accordance with article 590 of the *Code of Civil Procedure*.

Following a modification to the compensation criteria, the Court approved the Settlement on November 29, 2023. The judgment can be accessed here: [proactio.ca/transvaginalmesh](https://proactio.ca/transvaginalmesh).

**MAKING A CLAIM**

The Settlement Agreement provides a process to assess Class Members’ eligibility and, if applicable, the amount owed to Class Members as part of the Settlement Agreement. Class Members must submit a duly completed Claim Form and provide their relevant medical records. These documents will be reviewed by a urologist, who will determine if the Class Member is eligible to receive compensation as part of the Settlement Agreement, and if so, the amount of said compensation. The urologist will make this determination based on case assessment criteria agreed upon between the Defendant and the Representative Plaintiff. You may contact Class Counsel to obtain details regarding the case assessment criteria and how they may apply to you.

**To partake in the Settlement Agreement, you will need to complete and submit a Claim Form (including the necessary supporting documentation) to Proactio before March 18, 2024.**

**If you do NOT submit your claim on time, you will not be eligible for any benefits under the Settlement Agreement.**

**In order to determine your eligibility and to obtain more information about the Settlement Agreement, please communicate with Class Counsel at [jlambert@lambertavocats.ca](mailto:jlambert@lambertavocats.ca).**

**BE ADVISED** that on April 28, 2023, the Court also authorized the discontinuance of the class action with respect to the Altis and Restorelle Y mesh products. **Therefore, persons who have received implantation of an Altis or Restorelle Y product are no longer covered by the class action.** Limitation periods (i.e. prescription) are no longer suspended and began to run again on June 12, 2023. After the limitation periods, your right to sue will be extinguished.

**FOR MORE INFORMATION**

If you have questions about the class action and/or the impact of the refusal of approval of the Settlement Agreement, please contact Class Counsel at:

Mtre Jimmy Ernst Jr. Laguë Lambert  
Mtre Loran-Antuan King  
**LAMBERT AVOCATS**  
1111, Saint-Urbain St., #204  
Montreal, QC, H2Z 1Y6  
Tel.: (514) 526-2378  
Fax: (514) 878-2378  
Email: [jlambert@lambertavocats.ca](mailto:jlambert@lambertavocats.ca)

*The publication of this Notice was authorized by the Superior Court of Quebec*